Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
FDA, Biogen mull Tysabri label changes
The FDA is huddling with Biogen Idec and Elan on amendments to Tysabri's label. The reason, of course, is the news of two cases of the brain disorder progressive multifocal leukoencephalopathy, or PML, that emerged in late July.
In a notice on the agency's website, the FDA reiterated its belief that Tysabri taken on its own may generate a smaller risk of PML than when it's taken in combo with other meds that alter the immune system.
Compared with the response the last time PML emerged in Tysabri patients, it's mild. As you know, Tysabri was pulled from the market when PML first cropped up, but was allowed back on the market on a strict risk-management program, under which patients using the drug are monitored for infection. Investors showed their relief by pushing Biogen shares up by about 2 percent to $53.48, and Elan shares by 5 percent, to $14.25.
- check out the release
- read the Wall Street Journal story
- see the item in the Wall Street Journal Health Blog
Related Articles:
Biogen: Tysabri patients have PML
Analysts: Tysabri scrips will suffer
Biogen CEO: Tysabri to reach $1B in 2008
Biogen CEO: Tysabri patients will get PML
After reintroduction, Tysabri builds patient base
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


